Home > Journals > Acta Vulnologica > Past Issues > Acta Vulnologica 2004 June;2(1-2) > Acta Vulnologica 2004 June;2(1-2):9-11

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

ACTA VULNOLOGICA

A Journal on Physiopathology and Therapy of Chronic Cutaneous Ulcers


Official Journal of the Italian Association for Cutaneous Ulcers
Indexed/Abstracted in: EMBASE, Scopus, Emerging Sources Citation Index


eTOC

 

ORIGINAL ARTICLES  


Acta Vulnologica 2004 June;2(1-2):9-11

language: Italian

Clinical evaluation of Sorbact® in the treatment of infected pressure sores

Mussi C., Salvioli G.

Centre of Gerontologic Evaluation and Research University of Modena and Reggio Emilia, Italy


PDF  


Aim. Pressure sores present a high risk of becoming infected and chronic. The bacteria adsorbing dressing Sorbact® is able to lower the concentration of pathogenic microorganisms in the infected ulcers without pharmacological activity, but by hydrophobic interaction that takes place between 2 hydrophobic surfaces: the Sorbact® dressing and the microbial cell surface that bind to each other. As a result, when Sorbact® is changed the microorganisms that bind to the dressing are removed from the ulcer. The aim of the trial was to verify how Sorbact® can reduce the signs of infection in a group of patients suffering from infected pressure sores.
Methods. Thirty-three patients showing at least one infected pressure sore were enrolled and randomized in 2 groups: the control group (14 patients, treated according to specific guidelines) and the “Sorbact®” group (19 patients, who received the same treatment, except that the usual dressing was substituted with Sorbact®).
Results. Patients treated with Sorbact® showed a significant improvement in ulcer’s bed colour (94.7% vs 71.4%; p=0.034), an increase of cells debris dissolution (52.6% vs 42.8%; p=0.048), a reduction of both oedema and perilesional erythema (78.9% vs 57.1%; p=0.028) and a reduction in days of treatment (9±2 vs 11±2.1; p=0.041) compared to the patients in the control group.
Conclusion. Sorbact®’s ability to “bind” the hydrophobic pathogenic microorganisms (bacteria and fungi) and to lower their concentration in infected ulcers has been confirmed in our trial; in fact, by adding Sorbact® to the usual systemic antibiotics, we could increase the positive results rate, in a significantly shorter time. Sorbact® therefore has proved to be a useful dressing in the first line treatment of pressure sores, because it speeds up the control of infection and, consequently, the healing process.

top of page

Publication History

Cite this article as

Corresponding author e-mail